- Home
- GLMD vs TOVX Comparison
GLMD vs TOVX Comparison
Compare GLMD & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLMD | TOVX |
|---|---|---|
| Founded | 2000 | 2001 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6M | 7.3M |
| IPO Year | 2014 | 2006 |
Fundamental Metrics
Financial Performance| Metric | GLMD | TOVX |
|---|---|---|
| Price | $0.86 | $0.19 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 184.4K | ★ 2.8M |
| Earning Date | 11-26-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.74 | $0.17 |
| 52 Week High | $3.61 | $2.08 |
Technical Indicators
Market Signals| Indicator | GLMD | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 35.20 | 38.79 |
| Support Level | $0.95 | $0.17 |
| Resistance Level | $0.99 | $0.24 |
| Average True Range (ATR) | 0.09 | 0.02 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 11.25 | 24.56 |
Price Performance
Historical ComparisonAbout GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.